Effects of type 2 diabetes mellitus on the pharmacokinetics of berberine in rats

Abstract Context: Berberine is an active alkaloid isolated from Rhizoma coptidis [Coptis chinensis Franch. (Ranunculaceae)] that is widely used for the treatment of diabetes, hyperlipidemia and hypertension. However, the pharmacokinetics of berberine in normal rats and type 2 diabetes mellitus (T2DM) model rats are not clear. Objective: This study compares the pharmacokinetics of berberine between normal and T2DM model rats. Materials and methods: The T2DM model rats were fed with high fat diet for 4 weeks, induced by low-dose (30 mg/kg) streptozotocin for 72 h and validated by determining the peripheral blood glucose level. Rats were orally treated with berberine at a dose of 20 mg/kg and then berberine concentration in rat plasma was determined by employing a sensitive and rapid LC-MS/MS method. Results: The significantly different pharmacokinetic behaviour of berberine was observed between normal and T2DM model rats. When compared with the normal group, Cmax, t1/2 and AUC(0–t) of berberine were significantly increased in the model group (17.35 ± 3.24 vs 34.41 ± 4.25 μg/L; 3.95 ± 1.27 vs 9.29 ± 2.75 h; 151.21 ± 23.96 vs 283.81 ± 53.92 μg/h/L, respectively). In addition, oral clearance of berberine was significantly decreased in the model group (134.73 ± 32.15 vs 62.55 ± 16.34 L/h/kg). Discussion and conclusion: In T2DM model rats, the pharmacokinetic behaviour of berberine was significantly altered, which indicated that berberine dosage should be modified in T2DM patients.

[1]  W. Wang,et al.  Metformin ameliorates podocyte damage by restoring renal tissue nephrin expression in type 2 diabetic rats , 2017, Journal of diabetes.

[2]  Libin Zhan,et al.  ZiBu PiYin recipe prevents diabetes-associated cognitive decline in rats: possible involvement of ameliorating mitochondrial dysfunction, insulin resistance pathway and histopathological changes , 2016, BMC Complementary and Alternative Medicine.

[3]  Limei Zhao,et al.  Development and application of a UPLC-MS/MS method for simultaneous determination of fenofibric acid and berberine in rat plasma: application to the drug-drug pharmacokinetic interaction study of fenofibrate combined with berberine after oral administration in rats. , 2016, Biomedical chromatography : BMC.

[4]  Lu Liu,et al.  Effects of berberine on the pharmacokinetics of losartan and its metabolite EXP3174 in rats and its mechanism , 2016, Pharmaceutical biology.

[5]  Pedro J. Caraballo,et al.  Type 2 Diabetes Mellitus Trajectories and Associated Risks , 2016, Big Data.

[6]  Limei Zhao,et al.  Validated UPLC-MS/MS method for simultaneous determination of simvastatin, simvastatin hydroxy acid and berberine in rat plasma: Application to the drug-drug pharmacokinetic interaction study of simvastatin combined with berberine after oral administration in rats. , 2015, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[7]  G. Hatch,et al.  Berberine as a therapy for type 2 diabetes and its complications: From mechanism of action to clinical studies. , 2015, Biochemistry and cell biology = Biochimie et biologie cellulaire.

[8]  F. Lu,et al.  Berberine inhibits hepatic gluconeogenesis via the LKB1-AMPK-TORC2 signaling pathway in streptozotocin-induced diabetic rats. , 2015, World journal of gastroenterology.

[9]  R. Shankar,et al.  A comparison of glycaemic effects of sitagliptin and sulfonylureas in elderly patients with type 2 diabetes mellitus , 2015, International journal of clinical practice.

[10]  C. Aypak,et al.  Association of haematological parameters with bone mineral density in elderly diabetic women , 2015, Acta clinica Belgica.

[11]  S. Tangvarasittichai.  Oxidative stress, insulin resistance, dyslipidemia and type 2 diabetes mellitus. , 2015, World journal of diabetes.

[12]  Lucie M. Ramjan,et al.  Diagnosis of Type 2 Diabetes: The Experience of Jordanian Patients with Co-existing Depression , 2015, Issues in mental health nursing.

[13]  Rui-jie Zhang,et al.  Pharmacokinetic difference of berberine between normal and chronic visceral hypersensitivity irritable bowel syndrome rats and its mechanism , 2015, Archives of pharmacal research.

[14]  J. Franch-Nadal,et al.  Metabolic control and cardiovascular risk factors in type 2 diabetes mellitus patients according to diabetes duration. , 2015, Family practice.

[15]  Pei-Ming Yang,et al.  Berberine Inhibits the Metastatic Ability of Prostate Cancer Cells by Suppressing Epithelial-to-Mesenchymal Transition (EMT)-Associated Genes with Predictive and Prognostic Relevance , 2015, International journal of medical sciences.

[16]  N. Chung,et al.  Berberine induces apoptosis via ROS generation in PANC-1 and MIA-PaCa2 pancreatic cell lines , 2014, Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas.

[17]  J. Hohmann,et al.  Effects of Chelidonium majus extracts and major alkaloids on hERG potassium channels and on dog cardiac action potential - a safety approach. , 2015, Fitoterapia.

[18]  Rui-jie Zhang,et al.  Comparative pharmacokinetics of active alkaloids after oral administration of Rhizoma Coptidis extract and Wuji Wan formulas in rat using a UPLC–MS/MS method , 2015, European Journal of Drug Metabolism and Pharmacokinetics.

[19]  Yuan Liu,et al.  Effects of combinations of Xiexin decoction constituents on diabetic nephropathy in rats. , 2014, Journal of ethnopharmacology.

[20]  A. Scovassi,et al.  Berberine, an Epiphany Against Cancer , 2014, Molecules.

[21]  Limei Liu,et al.  Uncoupling protein‐2 mediates the protective action of berberine against oxidative stress in rat insulinoma INS‐1E cells and in diabetic mouse islets , 2014, British journal of pharmacology.

[22]  Bin Wang,et al.  Pharmacokinetic comparisons of berberine and palmatine in normal and metabolic syndrome rats. , 2014, Journal of ethnopharmacology.

[23]  Ding Zhao,et al.  Berberine improves neurogenic contractile response of bladder detrusor muscle in streptozotocin-induced diabetic rats. , 2013, Journal of ethnopharmacology.

[24]  Lijun Xu,et al.  The anti-diabetic effects and pharmacokinetic profiles of berberine in mice treated with Jiao-Tai-Wan and its compatibility. , 2013, Phytomedicine : international journal of phytotherapy and phytopharmacology.

[25]  B. Wollscheid,et al.  Malfunctioning of adipocytes in obesity is linked to quantitative surfaceome changes. , 2013, Biochimica et biophysica acta.

[26]  Jing Li,et al.  Sodium caprate augments the hypoglycemic effect of berberine via AMPK in inhibiting hepatic gluconeogenesis , 2012, Molecular and Cellular Endocrinology.

[27]  N. Nemoto,et al.  Alteration of hepatic glutathione peroxidase and superoxide dismutase expression in streptozotocin-induced diabetic mice by berberine , 2012, Pharmaceutical biology.

[28]  Faramarz Ismail-Beigi,et al.  Clinical practice. Glycemic management of type 2 diabetes mellitus. , 2012, The New England journal of medicine.

[29]  L. Jinhua,et al.  Berberine and Itraconazole Are not Synergistic in Vitro against Aspergillus fumigatus Isolated from Clinical Patients , 2011, Molecules.

[30]  Bing-Liang Ma,et al.  Lipopolysaccharide increased the acute toxicity of the Rhizoma coptidis extract in mice by increasing the systemic exposure to Rhizoma coptidis alkaloids. , 2011, Journal of ethnopharmacology.

[31]  Beppie van den Bogaerde,et al.  Clinical practice , 2011, European Journal of Pediatrics.

[32]  Frank B. Hu,et al.  Globalization of Diabetes , 2011, Diabetes Care.

[33]  HU FRANKB.,et al.  Globalization of Diabetes , 2011, Diabetes Care.

[34]  Cheah Js,et al.  Pathogenesis of type 1 and type 2 diabetes mellitus. , 1990 .

[35]  J. Cheah,et al.  Pathogenesis of type 1 and type 2 diabetes mellitus. , 1990, Annals of the Academy of Medicine, Singapore.

[36]  T. Mandrup-Poulsen,et al.  On the Pathogenesis of Insulin-Dependent Diabetes Mellitus — A Discussion of Three Recently Proposed Models , 1989 .